<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839929</url>
  </required_header>
  <id_info>
    <org_study_id>ADV-KT-02</org_study_id>
    <nct_id>NCT01839929</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF</brief_title>
  <acronym>PeACE</acronym>
  <official_title>A Multicenter, Open-label, Single-arm, Non-inferiority Study to Assess the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF® in Stable Kidney Transplant Patients Converted From a PROGRAF® Based Immunosuppressive Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of tacrolimus modified release
      formulation Advagraf® after conversion from Prograf® in stable kidney transplant patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glomerular filtration rate (GFR) at Week 24 from baseline</measure>
    <time_frame>Baseline and Week-24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure (BP) at Week 24 from baseline</measure>
    <time_frame>Baseline and Week-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c at Week 24 from baseline</measure>
    <time_frame>Baseline and Week-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tacrolimus blood trough level at Week 24 from baseline</measure>
    <time_frame>Baseline and Week-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, physical exam., vital signs and labo tests</measure>
    <time_frame>For 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall frequency of acute rejection</measure>
    <time_frame>For 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Prograf/Advagraf</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>conversion from Prograf to Advagraf</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>oral</description>
    <arm_group_label>Prograf/Advagraf</arm_group_label>
    <other_name>FK506</other_name>
    <other_name>tacrolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advagraf</intervention_name>
    <description>oral</description>
    <arm_group_label>Prograf/Advagraf</arm_group_label>
    <other_name>FK506E</other_name>
    <other_name>tacrolimus modified release formulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients received a kidney transplant at least 12 months ago prior to enrollment.

          2. Patients have taken unchanged dosage of Prograf® and remained stable serum level of
             tacrolimus at least for 12 weeks prior to enrollment.

          3. Patients have kept in unchanged immunosuppressive therapy (combination therapy) at
             least for 12 weeks prior to enrollment.

          4. Female patients of childbearing potential must have a negative urine or serum
             pregnancy test prior to enrollment, and agreed to the deliberate prevention of
             conception during the trial.

          5. Patients are considered clinically stable by observer's judgment.

          6. Patients must understand the purpose and risk of participating the trial and signed on
             the written consent.

        Exclusion Criteria:

          1. Patients have previously received an organ transplant other than a kidney.

          2. Patients have had acute transplant rejection within 12 weeks, or acute transplant
             rejection requiring antilymphocyte therapy within 24 weeks prior to enrollment.

          3. Patients newly diagnosed malignant tumors after organ transplant but the patients
             treated completely with basal or squamous cell carcinoma of the skin are excepted.

          4. Patients have a known hypersensitivity to Prograf® or tacrolimus.

          5. Patients whose medical condition are able to interfere with the study objectives.

          6. Patients who are at the risk of drug abuse or mental disorders or communicate
             difficulties with the observer.

          7. Patients have been participated in another clinical trial, or treated with drugs of
             clinical trial within 28 days prior to enrollment.

          8. Patients have been taken prohibited combination agents within 28 days prior to
             enrollment.

          9. Patients are pregnant or lactating.

         10. Patient are HIV-positive.

         11. Patients are not able to keep the scheduled visit.

         12. Patients whose GFR (MDRD) is in the level of &lt;30 mL/min.

         13. Patients who are at the condition of 'Creeping creatinine (defined by 20% increase
             within 6 months prior to enrollment)

         14. Patients whose SGPT/AST and/or SGOT/ALT levels have been elevated greater than 2 times
             the upper value of the normal range.

         15. Patients have FSGS or MPGN Type II as underlying diseases.

         16. Patients are with cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Korea, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tacrolimus</keyword>
  <keyword>immunosuppressant</keyword>
  <keyword>FK506</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

